S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
66,000% upside on tiny biotech? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
66,000% upside on tiny biotech? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
66,000% upside on tiny biotech? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Asian shares mostly rise after House approves debt ceiling deal
66,000% upside on tiny biotech? (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
66,000% upside on tiny biotech? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
66,000% upside on tiny biotech? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Forecast, Price & News

$3.99
-0.13 (-3.16%)
(As of 05/31/2023 ET)
Compare
Today's Range
$3.99
$4.20
50-Day Range
$3.00
$5.06
52-Week Range
$2.94
$9.79
Volume
2.25 million shs
Average Volume
647,409 shs
Market Capitalization
$332.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Atea Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
50.4% Upside
$6.00 Price Target
Short Interest
Healthy
2.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Atea Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.99) to ($2.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

366th out of 1,006 stocks

Pharmaceutical Preparations Industry

168th out of 492 stocks


AVIR stock logo

About Atea Pharmaceuticals (NASDAQ:AVIR) Stock

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVIR Stock News Headlines

Atea Pharmaceuticals Rejects Buyout Offer
Lithium Has Boomed And This American Stock Is Ready..
Lithium Has Been On A Crazy Rally Over The Last 3 Year's And This Stock Could Be Next!
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Earnings Scheduled For May 8, 2023
Q1 2023 Atea Pharmaceuticals Inc Earnings Call
AVIR Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (AVIR)
See More Headlines
Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVIR Company Calendar

Last Earnings
5/08/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVIR
Fax
N/A
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+46.7%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-115,910,000.00
Pretax Margin
18.75%

Debt

Sales & Book Value

Annual Sales
$351.37 million
Book Value
$7.41 per share

Miscellaneous

Free Float
72,724,000
Market Cap
$341.11 million
Optionable
Not Optionable
Beta
0.24

Key Executives

  • Dr. Jean-Pierre Sommadossi Ph.D. (Age 67)
    Founder, Chairman, CEO & Pres
    Comp: $981.5k
  • Ms. Andrea J. Corcoran J.D. (Age 61)
    CFO, Exec. VP of Legal & Sec.
    Comp: $653.39k
  • Mr. John F. Vavricka (Age 59)
    Chief Commercial Officer
    Comp: $528.52k
  • Dr. Janet M. J. Hammond M.D. (Age 63)
    Ph.D., Chief Devel. Officer
    Comp: $723.59k
  • Dr. Maria Arantxa Horga M.D. (Age 55)
    Chief Medical Officer
    Comp: $605.98k
  • Mr. Wayne Foster CPA (Age 54)
    CPA, Exec. VP of Fin. & Chief Accounting Officer
  • Ms. Jonae R. Barnes
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Ariyapadi N. Krishnaraj
    VP of Marketing
  • Mr. Adel Moussa Ph.D.
    Exec. VP of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D.
    Exec. VP of Early Stage Devel.













AVIR Stock - Frequently Asked Questions

Should I buy or sell Atea Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVIR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVIR, but not buy additional shares or sell existing shares.
View AVIR analyst ratings
or view top-rated stocks.

What is Atea Pharmaceuticals' stock price forecast for 2023?

3 analysts have issued twelve-month price targets for Atea Pharmaceuticals' stock. Their AVIR share price forecasts range from $4.00 to $8.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 46.7% from the stock's current price.
View analysts price targets for AVIR
or view top-rated stocks among Wall Street analysts.

How have AVIR shares performed in 2023?

Atea Pharmaceuticals' stock was trading at $4.81 at the beginning of the year. Since then, AVIR shares have decreased by 15.0% and is now trading at $4.09.
View the best growth stocks for 2023 here
.

Are investors shorting Atea Pharmaceuticals?

Atea Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,710,000 shares, a decline of 11.9% from the April 30th total of 1,940,000 shares. Based on an average daily trading volume, of 721,300 shares, the days-to-cover ratio is presently 2.4 days. Approximately 2.3% of the company's stock are sold short.
View Atea Pharmaceuticals' Short Interest
.

When is Atea Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our AVIR earnings forecast
.

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.08.

When did Atea Pharmaceuticals IPO?

(AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.

What is Atea Pharmaceuticals' stock symbol?

Atea Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVIR."

Who are Atea Pharmaceuticals' major shareholders?

Atea Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (13.88%), BlackRock Inc. (9.64%), Federated Hermes Inc. (2.44%), State Street Corp (2.23%), Geode Capital Management LLC (1.79%) and Acadian Asset Management LLC (1.33%). Insiders that own company stock include Franklin M Berger and Polly A Murphy.
View institutional ownership trends
.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atea Pharmaceuticals' stock price today?

One share of AVIR stock can currently be purchased for approximately $4.09.

How much money does Atea Pharmaceuticals make?

Atea Pharmaceuticals (NASDAQ:AVIR) has a market capitalization of $341.11 million and generates $351.37 million in revenue each year. The company earns $-115,910,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How can I contact Atea Pharmaceuticals?

The official website for the company is www.ateapharma.com. The company can be reached via phone at 857-284-8891 or via email at investors@ateapharma.com.

This page (NASDAQ:AVIR) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -